Xepenta-L Capsule SR is a sustained-release formulation combining Levosulpiride 75 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dysmotility. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic and antiemetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The sustained-release mechanism ensures prolonged therapeutic plasma levels, optimizing efficacy and improving patient compliance through once-daily dosing. Xepenta-L Capsule SR is indicated for patients with combined acid-peptic disorders and motility disturbances, providing a synergistic approach to symptom control and mucosal protection. It should be used under medical supervision, with caution advised in patients with hypersensitivity to either component, severe hepatic impairment, or pre-existing neurological conditions. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic benefits and minimize potential risks.

Dosage & How to Use

Dosage information not available. Please consult your doctor or pharmacist.

Safety information not available for this product. Please consult your doctor or pharmacist.